Labcorp (NYSE:LH) Shows Strong Q2 2026 Performance and Analyst Confidence

Font: Financial Modeling Prep  • Jul 30, 2026

• Barclays raised its price target for Labcorp to $320.00, signaling strong analyst confidence and a potential 1.32% upside.
• Labcorp reported robust second-quarter 2026 financial results, with revenue increasing by 5.8% to $3.73 billion and adjusted EPS growing by 14.9% to $4.99.
• The company raised its full-year 2026 guidance for both revenue and adjusted earnings, driven by consistent demand for its testing services and growth in its drug-development business.

Labcorp (NYSE:LH) is a global life sciences company that operates one of the world's largest clinical laboratory networks. It provides a wide range of diagnostic testing and drug development services. The company has a current market capitalization of approximately $25.90 billion and competes in the healthcare diagnostics and research sector.

An analyst from Barclays recently raised their price target for Labcorp to $320.00 on July 30, 2026. At the time, the stock was trading at $315.82. This new target represents a potential upside of approximately 1.32% from its price at the time of the announcement, signaling analyst confidence in the company's performance.

This positive outlook is supported by Labcorp's strong second-quarter 2026 financial results. The company reported a 5.8% increase in revenue to $3.73 billion. Its adjusted earnings per share (EPS) also grew by 14.9% to $4.99, beating analyst estimates as highlighted by Zacks.

Adjusted EPS is a measure of a company's profit per share, excluding one-time expenses, to show its core operational profitability. Labcorp's revenue growth was driven by a 4.2% increase in organic growth, a 1.2% contribution from acquisitions, and a 0.4% benefit from foreign currency exchange rates.

Following the strong quarter, Labcorp raised its full-year 2026 guidance for both revenue and adjusted earnings. As highlighted by Reuters, this decision was based on steady demand for its testing services and growth in its drug-development business, reinforcing the company's positive momentum.